Enteric-coated mycophenolate sodium (myfortic®): An overview of current and future use in transplantation

Drugs

Volumn 66, Issue SUPPL. 2, 2006, Pages 1-8

  Kaplan, Bruce ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN G; CYCLOSPORIN G2; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; ENTERIC COATED TABLET; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDIGESTION; INFECTION; KIDNEY TRANSPLANTATION; QUALITY OF LIFE; REVIEW; SMALL INTESTINE ABSORPTION;

EID: 33751503445     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666010-00001     Document Type: Review

References (47)

1. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996; 10: 77-84
2. Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000; 47: 215-45
3. Barten MJ, Gummert JF, van Gelder T, et al. Flow cytometric quantitation of calcium-dependent and -independent mitogen-stimulation of T cell functions in whole blood: inhibition by immunosuppressive drugs in vitro. J Immunol Methods 2001; 253: 95-112
4. Barten MJ, van Gelder T, Gummert JF, et al. Novel assays of multiple lymphocyte functions in whole blood measure: new mechanisms of action of mycophenolate mofetil in vivo. Transpl Immunol 2002; 10: 1-14
5. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1231-325
6. Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-32
7. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-37
8. Meier-Kriesche HU, Steffen BJ, Hochberg AM, et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 2003; 75: 1341-6
9. Meier-Kriesche HU, Ojo AO, Leichtman AB, et al. Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients. J Am Soc Nephrol 2000; 11: 2366-70
10. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405-9
11. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 27: 261-6
12. Knoll GA, MacDonald I, Khan A, et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381-6
13. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17: 200-5
14. Hardinger KL, Brennan DC, Lowell J, et al. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transplant Int 2004; 17: 609-16
15. Tierce JC, Porterfield-Baxa J, Petrilla AA, et al. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transplant 2006; 19: 779-84
16. Arms W, Breuer S, Choudhury GT, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005; 19: 199-206
17. Hawthorne AB, Mahida YR, Cole AT, et al. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 1991; 32: 77-83
18. Budde K, Glander P, Diekmann F, et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Exp Opin Pharmacother 2004; 5: 1333-45
19. Novartis Pharma AG. myfortic® (mycophenolic acid) summary of product characteristics. 10 October 2003
20. Arns W, Gies M, Choi L, et al. Absorption characteristics of myfortic®, an enteric-coated formulation of mycophenolic acid. Int J Clin Pharmacol Therapeut 2006; in press.
21. Pescovitz MD, Conti D, Dunn J, et al. Intravenous mycophenolate mofetil: safety, tolerability and pharmacokinetics. Clin Transplant 2000; 14: 179-88
22. Tedesco-Silva H, Bastien M-C, Choi L, et al. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil. Transplant Proc 2005; 37: 852-5
23. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001; 23: 305-15
24. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998; 64: 672-83
25. Mourad M, Malaise J, Chaib Eddour D, et al. Correlation of mycophenolic acid pharmacokinetic parameters with adverse events in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001; 47: 88-94
26. Granger DK. Enteric-coated mycophenolate sodium: results of two pivotal global multicenter trials. Transplant Proc 2001; 33: 3241-4
27. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004; 4: 231-6
28. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004; 4: 237-43
29. Budde K, Knoll G, Curtis J, et al. Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study. Transplant Proc 2005; 37: 912-5
30. Kumar M, Chan L, Oppenheimer F, et al. on behalf of the ERL301 and 302 study groups. Experience with myfortic1 (EC-MPS) in elderly de novo and maintenance renal transplant patients. J Am Soc Nephrol 2005; 16: 823A
31. Chan L, Arns W, Knoll G, on behalf of the ERL 301 and 302 study groups. Myfortic® (enteric coated mycophenolate sodium, EC-MPS) is safe alternative to mycophenolate acid therapy in de novo and maintenance diabetic kidney transplant patients. J Am Soc Nephrol 2005; 16: 239A
32. Curtis J, Weir M, on behalf of ERL 302 study group. Experience with enteric coated mycophenolate sodium (EC-MPS, myfortic®) within African-American kidney transplant patients. J Am Soc Nephrol 2005; 16: 237A
33. Sollinger H, Tomlanovich S, Margreiter R, on behalf of the ERL 301 study group. Safety of myfortic® (entericcoated mycophenolate sodium, EC-MPS) when administered in combination with induction treatment in renal transplantation. J Am Soc Nephrol 2005; 16: 828A
34. Abbud-Filho M, Giron F, Hernandez E, et al. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: Interim results of a multicenter Latin American study. Transplant Proc 2004; 36: 1647-9
35. Massari P, Duro-Garcia V, Girón F, et al. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant patients. Transplant Proc 2005; 37: 916-9
36. Nashan B, Ivens K, Suwelack B, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: preliminary results from the myfortic1 prospective multicenter study. Transplant Proc 2004; 36: 521S-3S
37. David-Neto E, Turconi A, Giron F, et al. A study about the safety and tolerability of the conversion to enteric-coated mycophenolate sodium from mycophenolate mofetil in stable pediatric renal transplant recipients [Abstract 1517]. Am J Transplant 2004; 4 (Suppl 8): 575
38. Kamar N, Garrigue V, Karras A, et al. Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients. A randomized multicenter study. American Journal Transplantation 2006; 6: 1042-8
39. Cibrik DM, Meier-Kriesche H-H, Bresnahan B, et al. Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12 month randomized trial in renal transplant recipients. Transplantation 2006 (in press)
40. Budde K, Bosmans J-L, Zeier M, et al. Safety and efficacy of reduced or full dose of cyclosporine (Neoral®) in combination with mycophenolate sodium (myfortic®), basiliximab (Simulect®), and steroids in de novo kidney transplant recipients. Transplantation 2004; 78 (Suppl 2): 83
41. Chan L, Mulgaonkar S, Walker R, et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006; 81: 1290-7
42. Kleinman L, Faull R, Walker R, et al. Gastrointestinal-specific patient-reported outcome instruments differentiate between renal transplant patients with or without GI complications. Transplant Proc 2005; 37: 846-9
43. Baryalei M, Zenker D, Pieske B, et al. Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine. Transplant Proc 2003; 35: 1539-42
44. Cantarovich M, Tzimas GN, Barkun J, et al. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver transplant patients with renal dysfunction. Transplantation 2003; 76: 98-102
45. Lama R, Santos F, Algar FJ, et al. Lung with tacrolimus and mycophenolate mofetil: a review. Transplant Proc 2003; 35: 1968-73
46. Moreno JM, Rubio E, Gomez A, et al. Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation. Transplant Proc 2003; 35: 1874-6
47. Kobashigawa JA, Renlund DG, Gerosa G, et al. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic1) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant 2006; 25: 935-41